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The experiments presented were all conducted in the laboratories
of Dr.

Michael Davis and Dr. Dorothy W. Gallager of Yale University

and The Connecticut Mental Health Center.

They represent a series of

interrelated studies designed to evaluate the relationship between
biochemistry and behavior. The first study in this series - Experiment
1

in this thesis - was carried out during my senior year at Yale

College. It was included in this thesis as it is the most economical
way to provide background information necessary for the understanding
of the later experiments.

The second and third experiments are

comprised of work done during the summer prior to my second year of
medical school as well as in May and June prior to beginning the third
year.

Parts of this work were presenteed at National Meetings of the

Society for Neuroscience - in Cincinatti in 1980 and in Minneapolis in
1982.
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ABSTRACT
Spinal modulation of the acoustic startle response:
behavioral, pharmacological and biochemical studies
in the normal, supersensitive and desensitized animal.
David Isaac Astrachan
198-4

A major v goal of psyohopharmacology is to understand at a
cellular level how drugs interact with various chemical systems to
affect behavior.

To accomplish this a behavior is needed which is

quantifiable, amenable to pharmacological manipulations and generated
from a known neural circuit.

The acoustic startle reflex of the rat

is a quantifiable behavior sensitive to a wide variety of drugs which
has its final central nervous system synapse in the lumbar spinal
cord.

Therefore, analysis of the biochemical effects of drugs infused

into the spinal cord should provide a powerful tool for assessing the
relationship between pharmacology, biochemistry and behavior.

Direct administration of serotonin, norepinephrine, and their
agonists into the subarachnoid space of the lumbar spinal cord
(intrathecal infusion) produced a dose dependent increase in acoustic
startle magnitude.

The effects were specific since noradrenergic

antagonists prevented the increase in startle caused by noradrenergic
agonists but not by serotonin agonists while serotonin antagonists
blocked the facilitation caused by serotonin agonists but not by
noradrenergic agonists.

In contrast neither dopamine nor its agonist

had any effect on startle magnitude at any of the doses tested.

The

magnitude of the behavioral facilitation caused by alpha-1-agonists
correlated highly with the degree of alpha-1-adrenoceptor occupation
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measured by ^H-prazosin binding in lumbar spinal tissue.

The more

receptors that were occupied, the greater the behavioral change
observed.

Intrathecal administration of the noradrenergic neurotoxin

6-hydroxydopamine (6-OHDA) produced a 95? decrease in spinal
norepinephrine and markedly enhanced the behavioral response to
intrathecal noradrenergic agonists as well as the number of
alpha-1-adrenoceptors (denervation supersensitivity).

The correlation

between the increased behavioral sensitivity to norepinephrine
agonists and the increase in the number of alpha-1-adrenoceptors
caused by 6-OHDA over time was 0.99.

Prior intrathecal infusion of the alpha-1-noradrenergic agonist
phenylephrine prevented the excitatory effects of subsequent alpha-1
agonists infused 6 hours later on acoustic startle (behavioral
desensitization).

This desensitization was associated with a decrease

in the number of alpha-1-adrenoceptor sites in the lumbar spinal
cord.

Taken together these data indicate that by analyzing biochemical,
pharmacological and behavioral processes in a specific region of the
central nervous system, extremely high correlations can be found
between biochemical

(binding parameters) and behavioral (changes in

acoustic startle response) measures.

Moreover, they indicate that

this model system may be particularly suitable for addressing more
subtle questions about receptor mechanisms and behavior in the
vertebrate.

Eventually this system can be used to analyze the

relationship between intracellular events and behavior.
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Introduction

Psychopharmacology is a science that attempts to bridge the gap
between the model systems approach of the basic scientist and the more
global observations and theories of behavioral scientists.

By the use

of simple behaviors amenable to observational, biochemical,
physiological and pharmacological analyses conclusions that are made
can be tested directly with a minimum of confounding variables.

A

major goal of psychopharmacology is to understand at a cellular level
how drugs interact with various chemical systems to affect behavior.
The central nervous system relies on these chemicals -neurotransmitters -- for interneuronal communication.

Drugs, which

may mimic or antagonize these endogenous transmitters, are used as
tools for probing transmitter systems.

The resultant behavioral

changes that accompany drug administration offer clues to how
neurotransmitters modulate behavior.

The more one is able to

specifically examine the mechanisms of drug action on neuronal systems
with the tools offered by biochemistry, physiology and pharmacology
the clearer the information possible regarding how drugs affect
neuronal processes which ultimately affect behavior.

Behaviors range in complexity with the simplest behaviors
involving monosynaptic reflex arcs.
easier it should be to study.

The more simple the behavior the

It is no wonder then that the most

definitive work on the neuronal bases of drug action,
neurotransmission and behavioral plasticity have been done in
invertebrates, most specifically on the siphon withdrawal reflex of
the Aplysia or sea slug (33).

The first step in the endeavor was to
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delineate the neural circuit mediating the behavior being measured.
Following this it was possible to characterize the neurotransmitters
modulating transmission along this circuit.

Finally,

it has been

possible to begin to determine at a cellular level how changes
produced by neurotransmitters at specific synaptic regions produce
behavioral changes.

Comparable levels of analysis have not yet been

possible in intact vertebrate systems, primarily because few
vertebrate behaviors are simple enough to have a neural circuit
amenable to a similar kind of experimental analysis.

The short latency acoustic startle reflex in the rat is one
vertebrate behavior which seems to provide an ideal system for
studying behavioral and pharmacological plasticity.

The startle

reflex has proven to be a useful measure for studying how drugs effect
sensory-motor reactivity (13). Acoustic startle amplitude is highly
dependent on the characteristics of the eliciting stimulus and this
tight degree of stimulus control allows nonzero baselines to be
established against which to test drugs as well as lesions or
electrical brain stimulation.

The entire primary neural circuit has

been recently worked out and shown to be quite simple involving only
four synapses within the central nervous system (20).
posteroventral cochlear nucleus to 2)
the lateral lemniscus to 3)
and finally to 4)

These are 1)

the dorsal and ventral nuclei of

the nucleus reticularis pontis caudalis

lower motor neurons of the spinal cord.

With the

circuit now delineated it is possible to determine exactly where and
even how drugs act within this pathway to alter neuro transmission and
ultimately affect behavior.
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Generally,

it has been assumed that drug effects are mediated by

the brain, once peripheral effects have been ruled out.

However, like

most behaviors studied in psychopharmacology the startle response
ultimately involves spinal motor neurons for its expression.

These

spinal motor neurons are known to receive dense modulating input from
neurons located in the brainstem (10,12,47) and the importance of the
spinal cord in mediating behavioral drug effects has been demonstrated
(49,69,71).

Yaksh and co-workers have described a method that allows

direct infusion (intrathecal administration) of compounds onto the
spinal cord in waking rats (70) and have shown these compounds to
remain localized about the tip of the catheter with negligible
diffusion into other areas of the CNS.

As the final synapse of the primary acoustic startle circuit
occurs in the spinal cord it is now possible with the use of
intrathecal catheters to infuse drugs directly onto a specific area of
the central nervous systems involved in a specific and quantifiable
behavior.

It should also be possible to examine the area involved in

the behavior by removing the tissue and biochemically determining at
the cellular level how drugs interact with various neurotransmitter
systems to affect behavior.

The present series of experiments were

designed towards this purpose.

Experiment 1_:

Spinal modulation of the acoustic startle response:

the

role of norepinephrine, serotonin and dopamine.

Systemic administration of serotonin (5-HT) , norepinephrine (NE)
or dopamine (DA) agonsits have been shown to increase both acoustic
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and tactile startle (13).

5-Methoxydimethyltryptamine, a 5~HT

agonist, given systemically produces large increases in acoustic
startle magnitude (16).

Combinations of drug which increase central

nervous system levels of 5-HT such as L-tryptophan and pargyline (a
monoamine oxidase inhibitor) also increase acoustic startle and this
effect can be blocked by pretreatment with the 5~HT synthesis
inhibitor p-chlorphenylalanine or by administration of varoius 5-HT
antagonists (13).

Most available data suggest that norepinephrine is excitatory to
acoustic startle.

Drugs that increase availability of central NE by

blocking its reuptake, such as moderate doses of desipramine or
chiordesipramine,

increase acoustic startle (19).

Conversely,

depletion of NE by lesions of the NE-containing cell bodies in the
locus coeruleus depresses both acoustic and tactile (1) startle.

In

addition, the alpha-1 adrenergic antagonist phenoxybenzamine depresses
startle at doses known to block adrenergic receptors (35).

NE may

also help mediate the excitatory effects of high doses of amphetamine
since pretreatment with phenoxybenzamine blocks the excitatory effects
of 1-amphetamine (35) and pretreatment with the NE synthesis inhibitor
FLA-63 blocks the excitatory effects of d-amphetamine (36).

High doses of d- and 1-amphetamine in addition to releasing
endogenous norepinephrine from nerve terminals also causes a marked
release of dopamine.

The excitatory effects of high dose amphetamine

on acoustic startle is also blocked by pretreatment with the DA
antagonists haloperidol or pimozide (35).

Furthermore, the directly

acting DA agonist apomorphine also increase acoustic startle and this
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effect can be blocked by haloperidol or pimozide (14,35).

The results

of these systemic drug studies suport the idea that enhancement of DA
transmission increases startle amplitude.

Anatomical studies indicate that spinal motor neurons receive
dense input from 5~HT, NE and DA containing neurons located in the
brainstem (10,12,14).

Single unit recording studies indicate that

both 5-HT and NE facilitate excitation of motor neurons produced by
afferent stimulation (39,68).

This increase in excitability occurred

without a direct increase in the firing of these motor neurons
consistent with a role for NE and 5_HT as neuromodulators within the
spinal cord.

Behavioral studies indicate that 5-HT or NE facilitate

spinal reflexes in spinalized or decerebrate animals (2,3,40,52).
Thus,

it is possible that the excitatory effects on startle produced

by systemic administration of monoamine agonists result from a direct
modulatory action in the spinal cord.

Using a modification of the intrathecal technique developed by
Yaksh and his coworkers the present experiments were designed to test
the effects of intrathecal administration of 5~HT, ME, DA, and their
agonists on the acoustic startle reflex.

Subj ects

Male Sprague-Dawley, Charles River rats (350-450 g) were used in
this and all subsequent experiments.

Rats were housed in group cages

(4-5 per cage) until intrathecal implantation at which time they were
then housed singly.

They were kept in a colony room with a reverse

light-dark cycle (12h-12h).

Food and water were continously
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available.
Preparation of the Animals:

Catheter Implantation

Animals were anesthetized with halothane and positioned with
blunt ear bars in a Kopf stereotaxic instrument.

The cisterna magna

was exposed and the overlying membrane punctured.
polyethylene tubing (PE 10)

An 8.5~cm length of

fused to a 3«5~cm length of PE-20 tubing

was inserted into the cisterna magna and gently "snaked" down over the
spinal cord to terminate above the lumbar enlargement as described by
Yaksh and Rudy (70).

The PE 20 portion of the catheter was secured

between wound clips used to close the incision.

The catheter was then

filled with sterile saline and the rats allowed to recover for 1 week.
For animals housed longer than four weeks with chronic catheters a
slight modification of the implantation procedure was used (37).

This

involved drilling a small hole through the occipital and parietal
bones of the skull and placing the PE 20 part of the catheter through
these holes.

This firmly anchored the catheter and prevented its

accidental removal that frequently occurred in animals housed for more
than four weeks catheterized in the usual way.

Measurement of acoustic startle amplitude.

Five separate stabilimeter devices were used to record the
amplitude of the startle response.

Each stabilimeter consisted of an

8x15x15 Plexiglass and wire mesh cage suspended within a 25 x 20 x
20 cm steel frame.

Within this frame, the cage was sandwiched between

four compression springs above and a 5 x 5 cm rubber cylinder below
with an accelerometer (MB Electronics type 302)

located between the
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bottom of the cage and the top of the rubber cylinder.

Cage movement

resulted in displacement of the accelerometer and the resultant
voltage was fed through a matched accelerometer amplifier (MB
Electronics model N 504), the output of which was proportional to the
velocity of accelerometer displacement.

The amplified signal then was fed to a specially designed
sample-and-hold circuit.

Basically,

this current consisted of five

channels, one for each stabilimeter, and was used to sample the peak
accelerometer voltage that occurred during a 20-msec time band
immediately after the onset of the startle-eliciting stimulus.
Immediately prior to this sample period, each channel was discharged
so that any spontaneous activity occurring between stimulus and stored
in one of each of the five channels.

Immediately after the sample

period, the output of each of the five channels was digitized through
a specially designed analog-to-digital convertor and fed into a PDP-11
computer.

Startle amplitude could vary from 0 to 160,

allowing

appreciable resolution among various startle amplitudes.

The five stabilimeters were located in a 2.5 x 2.5 x 2 m, dark,
ventilated, sound-attenuated chamber (Industrial Acoustic Co.,

IAC).

They were placed 1.1 meters from an Altec high frequency loudspeaker,
which was used to provide a 90-msec noise burst generated by a
Grason-Stadler noise generator, amplified through an Altec 100-W power
amplifier, and shaped through a Grason-Stadler electronic switch to
have a rise-decay time of 5 msec. Background white noise provided by a
Grason-Stadler white noise generator.

The intensity of the noise

burst (110 dB) and the background white noise (55 dB) was measured
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with a General Radio model 1551-C sound level meter (A scale) by
placing the microphone in each cage and positioning the cages to have
comparable readings.

Testing Procedure

One week after implantation rats were placed in the stabi1imeters
and 5 min later a program began which gave startle-eliciting tones
every 20 sec for

min.

This constituted the pre-drug baseline.

They were then removed from the test cages and infused with 18 ul of
drug dissolved in sterile salilne (pH 7.4) at a rate of 5 ul/min.

Ten

ul of drug was actually delivered onto the spinal cord while the
remaining 8 ul occupied the internal volume of the catheter.

Right

after infusion the rats were returned to test cages and immediately
given tones every 20 sec for 1 hour.

The post drug infusion scores

for each rat were compared with their respective pre-drug baseline to
determine the changes in startle amplitude following drug treatment.
Rats were tested only once and then discarded.

Following testing the

catheters were removed and examined for possible leakage or clogging.
Only results from animals with intact and unclogged catheters were
included as data.

Results

Intrathecal administration of 100-200 ug of 5-HT (free base)
increased startle by about 50$ immediately after administration, but
the effect only lasted for a few minutes.

Pretreatment with the

monoamine oxidase inhibitor pargyline (25 mg/kg)
markedly enhanced the excitatory effect of 5~HT.

1

hour earlier
Following pargyline,
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5-HT (6.25,

25 or 50 ug) caused a dose-dependent increase in startle

that now lasted for 30-40 minutes at the highest dose.

An overall

analysis of variance using each animal's postinfusion minus
preinfusion change scores revealed a dose-dependent increase in
startle amplitude over these conditions, F (3/16)

= 11.86 p < 0.001,

that was linearly related to the log dose given, Flin (1/16)

= 22.51,

p < 0.001 .

Intrathecal administration of the direct 5-HT agonist,
5-methoxy-N,N-dimethyltryptamine (5-MeODMT) produced a marked and
immediate increase in acoustic startle amplitude.
Fig. 1

The left panel of

shows the time course for the most effective dose (50 ug)

relative to the saline condition.

The right panel of Fig.

1

shows the

dose-response curve expressed as the mean change from the preinfusion
baseline to the first 10 min postinfusion + S.E.M.

An overall

analysis of variance using these change scores revealed a significant
dose-response effect, F (3/8) = 11.44, p < 0.01, that was linearly
related to the log dose used, Flin (1/18) = 30.17, p < 0.001.
Intrathecal NE immediately increased acoustic startle, but the effects
decayed very rapidly, within about 4 min.
used (12.5, 25, 50,

All doses of NE that were

and 100 ug free base) showed similar effects:

a

rapid initial increase in startle followed by an immediate decay.
Analyses of the postinfusion-preinfusion change scores for each animal
revealed a significant effect of NE, F (1/15)

= 11.56, p < .005.

Over

this dose range, however, a significant dose-response relationship was
not obtained.
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The left panel of Figure 2 shows the results of intrathecal
infusion of 50 ug of the alpha-1

adrenergic agonist phenylephrine.

Intrathecal phenylephrine increased startle amplitude for roughly 40
min following infusion.

This effect was directly related to the dose

that was used, F (3/13)

= 8.08, p < 0.001, as shown in the right panel

of Figure 2.
phenylephrine,

In contrast to the alpha-1

adrenergic agonist

intrathecal administration of the beta-adrenergic

agonist isoproterenol did not alter acoustic startle at any of the
doses tested (25,

100,

or 400 ug).

Table 1 shows the results of pretreating rats intraperitoneally
with 5-HT or NE antagonists 15 minutes prior to the intrathecal
infusion of either 5-MeODMT (50 ug) or phenylephrine (50 ug).
of 1.0 mg/kg of the alpha-1 adrenergic antagonist WB-4101

A dose

completely

blocked phenylephrine’s effect on startle but not that of 5-MeODMT.
In contrast, a dose of 1.0 mg/kg of the 5-HT antagonist cyproheptadine
completely blocked the effect of intrathecal 5-MeODMT but not that of
phenylephrine.

On the other hand, the beta-antagonist propranolol did

not block the increase in startle amplitude caused by either 5-Me0DMT
or phenylephrine.

The preceeding experiments demonstrate that either 5-HT or NE can
increase acoustic startle when applied directly onto the spinal cord.
Excitation following intrathecal 5-HT or 5~HT agonists appears to be
mediated through a 5-HT receptor.
acting 5-HT agonist, 5-MeODMT,

In the present study the direct

increased acoustic startle when applied

intrathecally and this effect was blocked by systemic administration
of the 5-HT antagonist, cyproheptadine, but not by the
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TABLE 1

Mean change in startle amplitude (± S.E.M.) from 0 to 20 minutes after
intrathecal 5-MeODMT or phenylephrine following intraperitoneal admin¬
istration of either saline, the alpha-l-noradrenergic antagonist
WB-4101, the 5-HT antagonist cyproheptadine or the beta-noradrenergic
antagonist propranolol.
All pretest drugs were given 15 minutes before intrathecal infusion of
test drugs. Per cent change relative to preinfusion baseline is shown
in parentheses.

Pretest drug

Test drug
5-MeODMT (50ug)

Saline
WB-4101, 0.2mg/kg
WB-4101, l.Omg/kg
Cyproheptadine, 0.2mg/kg
Cyproheptadine, 1.Omg/kg
Cyproheptadine, 5.Omg/kg
Propranolol, 20mg/kg
**P^0.01 relative to saline

26.1
—
18.0
9.0
-2.8
-5.2
20.5

8.0 (+130%)
+
+
•+
+
■+

4.3
4.6
1.6
2.4
6.0

(+98%)
(+37%)
(-8%)**
(-12%)**
(+96%)

Phenylephrine (50ug)

15.1 + 5.2 (+116%)
12.2 + 4.8 (+93%)
-0.7 + 3.0 (-10%)**
—
15.1 ■4* 3.2 (+111%)
—
14.6 + 4.0 (+101%)
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alpha-1-adrenergic antagonist WB-4101.

Other work has shown that the

increase in startle produced by intrathecal 5-HT is blocked by
systemic administration of the 5~HT antagonist, cinanserin (17).

Intrathecal NE appears to increase startle via stimulation of an
alpha-1 receptor.

Thus, the alpha-1

agonist phenylephrine increased

startle when applied intrathecally and this effect was blocked by the
alpha-1

antagonist WB-4101

nor cyproheptadine.

but not by the beta-antagonist propranolol

In contrast, intrathecal administration of the

beta-agonist isoproterenol did not affect acoustic startle.

In

contrast to 5~HT and NE, neither DA nor the DA agonist apomorphine
increased acoustic startle when given intrathecally.

This experiment clearly demonstrates the importance of the spinal
cord as a target for mediating drug effects on behavior.

Experiment 2:

Correlations between alpha-1

acoustic startle and alpha-1
lumbar spinal cord:

adrenergic stimulation of

adrenoceptor occupancy and number in rat

supersensitivity vs normal state.

For a drug to

function it must be able to induce a change in a cellular system.

One

mechanism by which a drug alters neuronal function is by its joining
with a specific recpetor on that cell.

This drug-receptor complex may

then lead to a change in cellular activity which may ultimately be
expressed as a behavioral change.

The functional consequences of alterations in neurotransmitter
receptors is important for the study of the neurochemical basis of
behavior.

Recently, _in vitro high affinity binding of

neurotransmitter substances to neuronal membranes has been used to
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identify and characterize certain kinetic parameters of receptors such
as affinity and number of recognition sites available for interaction
with neurotransmitters or drugs (72).

A relationship between

alterations in neurotransmitter binding sites and behavior can be used
to determine how binding parameters may relate to the functional state
of the receptor (11).
is needed which is:

In order to make such a correlation a behavior
1) altered by specific pharmacological

manipulations; 2) quantifiable;

and 3) generated from a specific area

of the CNS.

As has been shown, the acoustic startle response satisfies these
three criteria.

It is quantifiable and has been shown to be altered

by both noradrenergic and serotonergic agonists applied locally to a
specific area of the CNS.

Alpha-1-noradrenergic receptors have been

localized in the spinal cord and a specific alpha-1
in cAMP has been found in this tissue.

induced increase

In addition intrathecal

d-amphetamine, which acts indirectly to increase noradrenergic
transmission, has also been shown to increase the amplitude of
aocustic startle (15). The excitatory effects of d-amphetamine -- like
those of phenylephrine — can be blocked by systemic administration of
the alpha-1 antagonist, WB—4101, but not by the 5-HT antagonist
cyproheptadine, or the dopamine antagonist haloperidol

(15).

The acoustic startle reflex provides, therefore, a test system in
which quantifiable changes in behavior can be measured following
pharmacological manipulations in a limited part of the central nervous
system.

Examination of the lumbar spinal tissue in rats given

intrathecal infusions of alpha-1-adrenergic agonists should thus
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provide a method to determine the parameters of alpha-1-adrenergic
binding that may be important in mediating changes in behavioral
output.

Prazosin has been shown to have a preferential affinity for
alpha-1-adrenoceptor sites both in the peripheral (9,41) and central
nervous system (26,42,63).

Hence, tritiated prazosin was used in

these studies to evaluate the effects of various physiological and
pharmacological manipulations on alpha-1-binding sites.

Correlations between behavior and binding were made using two
different approaches.

The first series of studies evaluated if there

would be a correlation within animals, between the increase in the
acoustic startle response produced by intrathecal administration of an
alpha-1-agonist with the number of 3H-prazosin binding sites occupied
by that agonist. If the magnitude of the behavior is related to
receptor occupation, then increases in binding should be correlated to
increases in behavior.

The second series of experiments involved

altering the receptors themselves.

6-OHDA lesions have been shown to

cause significant increases in the number of alpha-1-adrenoceptors
(54,56,61,62).

If these receptors are involved in mediating the

behavioral response, then an increase in the number of binding sites
following denervation should be associated with an enhancement of the
behaviorial response produced by an alpha-1-agonist.

Moreover,

depending on the correlation between these two measures, it should be
possible to determine from these data the relationship between
receptor occupation and pharmacological efficacy in the normal and
denervated state.
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d-Amphetamine and Phenylephrine:

Receptor Occupation and Startle

Change Correlation

One week following implantation rats were tested for acoustic
startle following intrathecal administration of d-amphetamine or
saline.

Testing involved placing the rats in the stabilimeters and 5

min later giving startle eliciting noise bursts every 20 sec for 14
min to establish a pre-infusion baseline.

Rats were then removed from

the test cages and infused with 100 ug d-amphetamine dissolved in 10
ul of sterile saline followed by 8 ul of sterile saline to flush the
d-amphetamine solution from the catheter and to occupy the catheter's
internal volume.

Immediately following infusion rats were returned to

test cages and given noise bursts every 20 sec for 30 min.

Previous

work has shown that d-amphetamine's maximal effect on startle occurs
about 30 min after the drug is infused.

At the end of the 30 min test

session each rat was decapitated and a 2.5 cm section of the lumbar
cord was dissected out, weighed and frozen.

The decapitation and

dissection procedure took approximately 2-3 min.
weighed 214 + 22 mg per animal.
assayed.

Lumbar cord segments

Tissues were stored at -70 °C until

Preliminary experiments showed no significant difference in

binding between fresh tissue and tissue frozen under those conditions
for at least 3 weeks.

Assays were completed within this time period.

In a second group of rats the same procedures were repeated using
phenylephrine as a direct alpha-1-adrenergic agonist instead of
d-amphetamine.

In addition, half the rats were treated with 6-OHDA to

determine in a preliminary way if this would increase the
effectiveness of phenylephrine and, if so, to determine the
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correlation, within animals, between the response to phenylephrine and
receptor binding in normal and denervated animals.

To assure that the

treatment groups would have similar initial startle amplitude prior to
any treatment, all rats were placed in the stabilimeters and 5 min
later presented with startle-eliciting noise bursts every 20 sec for
10 min.

Based on the mean startle amplitude for each animal, the rats

were divided into two groups with each group having similar mean
startle amplitudes and variances.

All of the rats within one group

then received 20 ug of 6-OHDA dissolved in 10 ul of 0.155 ascorbic
acid;

the other matched group received an equal volume of the vehicle

(0.155 ascorbic acid).

The pH of both solutions was adjusted to 5.4

and the infusion rate was 10 ul/min.

Following infusion the catheters

were flushed with 8 ul of sterile saline.

Thus, 10 ul of 6-OHDA or

vehicle was actually delivered onto the spinal cord, while the
remaining 8 ul of saline occupied the catheter's internal volume.
Following infusion animals were returned to their home cages.

Animals were tested one week after receiving either 6-OHDA or
vehicle, using either 25 or 50 ug of phenylephrine which was infused
after a 14 min pre-infusion baseline.

After the infusion the rats

were returned to test cages and given noise bursts every 20 sec for 30
min. Experiment 1 showing phenylephrine's maximal effect on startle to
occur from 15 to 30 min after the drug's infusion.

At the end of the

test session lumbar spinal cords were removed as described
previously.

3H-Prazosin Binding:

In Vitro Estimation of Receptor Occupation

19

3H-prazosin binding assays were carried out as a slight
modification of the assay described by Greengrass and Bremner (26).
In these studies lumbar cord sections were homogenized (Polytron
PT-10/setting 8 for 20 sec)

in 40 volumes

Tris-HCl pH 8.0 (at 25 C).

One half of the resulting homogenate was

removed and stored on ice until assay.
"unwashed fraction".

(w/v) of ice cold 50 mM

This sample was labeled the

The remaining homogenate was further diluted

with 200 volumes (w/v) of cold Tris buffer (pH 7.4), resuspended and
centrifuged at 42,000 x g for 10 min;

the resulting membrane pellet

was resuspended and centrifuged two additional times.

Preliminary

experiments indicated that washing the membrane pellet three times was
sufficient to remove residual phenylephrine from the assay which may
have interfered with the binding of 3H-prazosin.
finally resuspended in 40 volumes

Membranes were

(w/v) of 50 mM Tris-HCl buffer, (pH

8.0), labelled the "washed fraction".

Aliquots (0.8 ml) of both the

"washed" and "unwashed" fractions were incubated in the presence of
ascorbic acid (0.1$), and single concentration of (0.7 to 1.0 nM)
3H-prazosin (Amersham-Searle S.A. 20.2 Ci/mM) and 0.05 M Tris HC1
buffer (pH 8.0) to 1 ml total volume.

Assays were analyzed in

triplicate, two additional assay tubes contained 1 uM WB-4101
Pharmaceuticals) to determine non-specific binding.
carried out at room temperature for 30 min;

(WB

Incubations were

after incubation the

samples were rapidly filtered through GF/B filters (Whatham Co., U.K.)
under low vacuum.

The filters were washed with three 8 ml aliquots of

ice-cold 50 mM Tris buffer (pH 7.4) and counted in a liquid
scintillation counter in 8 ml Econofluor (New England Nuclear).
Results are reported as specific prazosin binding per mg protein, by
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the method of Lowry et al.

(14) representing total binding minus

binding in the presence of 1 uM WB-4101.

Each animal had a specific

"unwashed" SB(UW) binding score and a specific "washed" SB(W) binding
per mg protein score.

An index of recept or

was calculated as the diff erence between the
Percent of

specific binding of 3H -prazosin.
was determined by the formula

%

occupied:

SB(W) - SB(UW)
x 100
Bmax

Phenylephrine Dose Response Curve Following 6-OHDA

One week following implantation, a total of 48 animals were
matched into four groups using the methods described above. Half the
rats in each group were lesioned with 20 ug of intrathecal 6-OHDA,
while the other half received an equal volume of vehicle.

One week

later animals were placed in the test cages and a preinfusion baseline
was established.

The animals were then removed from the test cages

and received either saline, 12.5,
intrathecally.

25,

or 50 ug of phenylephrine,

Immediately following infusion rats were returned to

test cages and given noise bursts every 20 sec for 30 min.

They were

then discarded.

6-OHDA Time Course:

Receptor Change, Startle Change Correlation

Animals were implanted and matched into two groups as described
before.

One group received 20 ug of 6-OHDA in 10 ul of 0.1% ascorbic
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acid while the other matched group received an equal volume of
vehicle.

At various time intervals following the infusions (3 days,

1, 2, or 4 weeks) both vehicle and 6-OHDA groups were tested for
acoustic startle following intrathecal administration of 12.5 ug of
the alpha-1 -agonist phenylephrine.

This involved the same procedure

of establishing a preinfusion baseline, removing the animals from the
test cages, infusing all of them with 12.5 ug of phenylephrine and
then returning them to the test cages for 30 min of startle eliciting
noise bursts.

Following testing lumbar cords were removed and

prepared for the 3H-prazosin binding assay.

Scatchard Analysis

At specific times after 6-OHDA or vehicle administration and
subsequent phenylephrine testing (3 days, 1, 2, or 4 weeks) animals
were killed and lumbar spinal cord tissues for each treatment group
were pooled .

Pooled tissues were homogenized in cold 1: 200 (w/v) of

Tris HC1 buffer (pH 7.4), centrifuged at 42,000 x g for 10 min,
resuspended and centrifuged two additional times.

The resulting

washed membrane pellets were resuspended in cold 1:40 (w/v) 50 mM Tris
HC1 buffer (pH 8.0).

Aliquots (0.8 ml) of this homogenate were

assayed for 3H-prazosin binding as described above in the presence of
varying concentrations of 3H-prazosin (0.05 to 2.0 nM).
binding was assessed by the addition of 1 uM WB-4101.

Non-specific
Quadruplicate

samples and duplicate non-specific binding values were obtained for
each concentration of 3H-prazosin.

The maximum number of binding

sites (Bmax) and apparent dissociation constant (KD) were estimated by
Scatchard analysis.

Protein concentrations were determined by the
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method of Lowry et al.

(38).

Determination of the Ki:

Phenylephrine Competition

Pooled tissue for 6-OHDA lesioned and vehicle treated animals
were analyzed for 3H-prazosin binding and its ability to be displaced
by the _in vitro addition of various concentrations of phenylephrine.
Washed lumbar cord membranes were prepared as described above and
incubated in the presence of 1 nM 3H-prazosin and various
concentrations of phenylephrine (1 x 10-3 M to 1 x 10-6 M) in the
presence or absence of 1 uM WB-4101.

Determination of Norepinephrine Content

Biochemical assay for catecholamines were performed using ligand
chromatography with electron detection as described by Reinhard and
Roth (50).

Briefly, tissue samples (ca. 20 mg, wet weight) were

sonically disrupted in 400 ul of 0.1 M perchloric acid containing 0.23
mM ascorbic acid (as an anti-oxidant), 75 nM dihydroxybenzyl amine;
(Aldrich Chemical Co., Milwaukee, WI). The homogenates were
centrifuged at 25,000 x g x 15 minutes and 300 ul aliquots of the
clear supernatants were retained for subsequent analysis.

The supernates were adjusted to pH 8.6 and applied to miniature
alumina columns (containing approximately 20 mg of acid-washed
aluminum oxide).

Passage of fluid through the columns was facilitated

by centrifuging the columns

(suspended in the mouths of 10 x 75 mm

test tubes) at 50 x g x 2 min.

The columns were washed with water

(which was discarded) and eluted with 120 ul of 0.1 M oxalic acid;

50
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ul of the eluate were applied to the LC for catechol analysis.

The chromatographic conditions for the model 420 Altex LC
(equiped with a Bioanalytical System Inc., LC-3 amperometric detector)
was as follows:

the mobile phase was a 0.1 M NaPhosphate buffer (pH

3.2) which contained 0.2 mM octane sulfonic acid)

(Regis Chemical Co.,

Morton Grove, IL), 0.1 mM ethylenediaminetetraacetic acid (EDTA), and
4$ (v/v) methanol;

a flow rate of 1.5 ml/min was used through an Altex

Ultrasphere - i.p. column.

Compunds were identified on the basis of

retention time and were quantitatively compared to authentic
standards, run the same day.

RESULTS

The correlation between the increase in startle caused by 100 ug
of intrathecal d-amphetamine and the 3H-prazosin binding sites
occupied is shown in Figure 3.

Occupation of binding sites was

defined as the "washed" minus "unwashed" specific 3H-prazosin binding
values corrected for protein concentrations.

Within the d-amphetamine

treated group the increase in startle could be directly correlated
with the number of receptors occupied for each animal tested r (5)
0.963, p < .001.

=

The data also show that minimal occupation of

alpha-1-adrenergic sites by the agonist is necessary to counteract a
net decrease in startle normally observed in these test conditions
(4,15).

A significant correlation was also found between the increase

in startle caused by either 25 or 50 ug of phenylephrine in both
lesioned and non-lesioned animals and the 3H-prazosin binding sites
occupied, r (16) = 0.50, p < 0.02.

However, following the intrathecal

PERCENT CHANGE IN STARTLE
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CHANGE IN RECEPTOR OCCUPATION

(fmole/mg protein)

FIGURE 3.
Correlation between estimated receptor occupation of
individual animals (washed minus unwashed) and percent startle
increase (mean amplitude startle measured from 15 to 30 minutes
post-infusion following lOOug d-amphetamine minus mean startle
amplitude over the 14 minute pre-drug baseline)..
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administration of saline no significant difference in binding was
observed between the ’unwashed*
’washed'

(98.9 fmoles of 3H-prazosin bound) and

(96.6 fmoles of 3H-prazosin bound) fractions when assayed at

equivalent dilutions in the presence of 0.75 nM 3H-prazosin.

Various doses of phenylephrine were tested for their effects on
acoustic startle response one week following either 6-OHDA lesion or
sham-lesion.

In both lesioned and unlesioned animals there was a

significant effect of varying the dose of phenylephrine on the
acoustic startle response, F (3/36)

= 6.18, p < .005 (Figure 4).

Moreover, there was a significant difference between the increase in
acoustic startle caused by the 12.5 ug dose of phenylephrine in
lesioned vs sham animals, _t (1.0)

= 3*31» p < .01,

indicating that

phenylephrine in a dose of 12.5 ug was able to induce a large increase
in acoustic startle in lesioned rats but not in sham animals.

The magnitude of the excitatory effect of phenylephrine in
acoustic startle increased as a function of the time, after 6-OHDA
administration, F (3.21) = 3*12, p < 0.05,

this effect was linear over

a time period from 3 days to 4 weeks, F lin (1,21) = 8.98, p < 0.01.
An increase in the number of specific 3H-prazosin binding sites in
animals lesioned with 6-OHDA at various time intervals (3 days, 1, 2,
or 4 weeks) also occured (Table 2).

A scatchard plot of data from

4-week 6-OHDA lesioned and sham-lesioned animals is shown in Figure 5.
This analysis indicated that the increase in specific 3H-prazosin
binding observed 4 weeks after pretreatment with 6-OHDA could be
attributed to an increase in the total number of binding sites (Bmax)
without a significant change in the dissociation constant (KD).

Table
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PERCENT CHANGE IN STARTLE

• 6-OHDA
100

75

50

25

0

-25 1-1-1-:-1-1
Saline
12.5
25
50
AMOUNT OF PHENYLEPHRINE (^g)

FIGURE A.
Mean change in startle amplitude (+S.E.M.) averaged
from 15 to 30 minutes post-drug infusion minus the startle averaged
over the 14 minute pre-drug period for three doses of phenylephrine
and saline in both 1 week 6-OHM lesioned and sham-operated animals,
n=6 at each point.
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TABLE 2

Dissociation constants (K_), receptor densities (B^ ) and phenyl¬
ephrine's ability to inhibit pHjprazosin (1 nM) binding (K^) of
alpha-1-noradrenergic receptors in control and lesioned tissue at
various time points.

Scatchard plots of [^Hjprazosin binding (0.05-2.0 nM) were deter¬
mined from pooled tissue for each group at each time point.
values were calculated from the equation:
K^ic50/(nfree ”dloliean-d)

IC^q values were obtained from inhibition curves. 5-8 rats at each
particular treatment.

6-OHDA

Vehicle

3
1
2
4

days
week
weeks
weeks

kd

®max

0.30
0.37
0.46
0.38

47.9
44.2
39.9
43.5

KiCnM)

2905
4688

kd

^max

0.30
0.30
0.42
0.40

51.6
53.8
53.7
60.3

Ki(nM)

3271
4511

B/F

(fmole/mg protein/nM)
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3H-PRAZOSIN BOUND (fmole/mg protein)

FIGURE 5.
Scatchard analysis of [^Hjprazosin binding to rat lumbar
spinal cord membranes from animals treated 4 weeks previously with
either 6-OHDA or vehicle. B/F is the ratio of specific bound [^H]prazosin to free [^H]prazosin. The slope of each individual plot
gives an estimate of the equilibrium dissociation constant (Kp at
25°C) and the intersection with the abcissa gives a measure of the
total number of binding sites (Bmav). (Vehicle KD«0.38 nM,
®max“^.5 fmol/mg protein; 6-OHDA Kd*0.40 nM, Rmax“60.3 fmol/mg
protein).
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2 presents the observed KD and Braax values in each of the 4 time point
groups.
rats,

The Ki values, coupled with constant KDs in sham vs. lesioned

indicates that the 6-OHDA lesion does not have a significant

effect on receptor affinity.

A correlation between the change observed in the maximal number
of binding sites (lesioned vs. sham) at each of the four time points,
and the mean percent change in startle following an intrathecal dose
of 12.5 ug phenylephrine is shown in Figure 6.

A high correlation was

found between the increase in the number of 3H-prazosin binding sites
and the magnitude of the startle increase, r (2)

= 0.99, p < 0.01.

An estimate for the number of receptors occupied was calculated
by "washed" minus "unwashed" 3H-prazosin binding values (corrected for
protein concentration) in animals exhibiting maximal behavioral
changes in response to drug infusion.

Comparing these numbers to the

Bmax values obtained by Scatchard analysis of tissue from respective
treatment groups gives the percentage of receptor occupied (Table 3)*
Occupation of approximately 30$ of the total alpha-1-adrenoceptors is
sufficient to produce a maximal increase in the startle response in
both control and lesioned animals.

Howe and Yaksh (29) have demonstrated that intrathecal 6-OHDA
depletes lumbar cord levels of NE within 1 day following treatment,
peaking at 2 weeks
after lesion.

(98%

depletion) and continuing for at least 4 weeks

In the present experiments, we examined the

localization of intrathecal 6-OHDA induced depletions of
norepinephrine at various levels of the neuraxis.

Intrathecal 6-OHDA

PERCENT CHANGE IN STARTLE
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CHANGE IN Bmax (6-OHDA-VEHICLE)

(fmole/mg protein)

FIGURE 6.
Correlation between increases in receptor number (E^y)
as described by Scatchard analysis and mean percent startle increase
in response to 12.5ug of intrathecal phenylephrine, ((startle aver¬
aged from 15 to 30 minutes post-drug infusion minus startle averaged
over a 14 minute pre-drug period) x 100).
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TABLE 3

Percentage of binding sites occupied in order to produce a significant
increase in startle response over controls.
Individual binding scores were computed for each animal and the mean
score for each treatment point was then compared to the Bmax to get an
estimate for the percentage of receptors occupied:
(specific binding washed - specific binding unwashed)

v , nn

X lull

Dmax
n = 5 at each treatment point.

6-OHDA pretreatment (12.5ug PE)
Vehicle pretreatment(50 ug PE)
No pretreatment (lOOug d-AMP)

Mean receptors
Bmax
occupied (fmol/
(fmol/mg
mg protein)protein)

Percentage
receptors
occupied

13.7
2.7
8.5
0.8
13.2 + 1.1

26%
23%
33%

53.7
36.9
40.0
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lesions of the lumbar cord caused significant reductions in NE levels
in the lumbar cord,

t

(16)

= 9.85, p < 0.001, but not in the brain

stem or cerebral cortex (Table 4).

Within the spinal cord a gradient

of NE depletion was found with greatest depletions in the lumbar and
thoracic areas
regions (3355).

(96% depletion), and less in the more rostral cervical
As previously reported (11), no significant

alterations of 5_HT levels in the lumbar cord were observed following
localized 6-0HDA injections (control = 218 + 25 ng/mg;

lesion = 196 +

19 ng/mg).

The purpose of the present study was to evaluate how changes in
alpha-1- adrenoceptor binding parameters could be correlated with
changes in functional alpha-1-adrenoceptor transmission, by measuring
the effects of alpha-1-agonists on a behavioral reflex.
with the results of experiment 1,

Consistent

intrathecal administration of the

alpha-1-adrenergic agonist phenylephrine or d- amphetamine increased
the amplitude of the acoustic startle reflex (15).

The excitatory

effect of intrathecal amphetamine appears to be due to its actions
within the spinal cord since supraspinal (intraventricular)
administration of amphetamine in equivalent doses does not increase
startle (Commissaris and Davis, unpublished).

In addition, Yaksh and

Rudy (70) have shown that radioactive substances of varing lipid
solubility infused into the lumbar enlargement of the rate spinal cord
remain localized in the region around the tip of the cathether with
little caudal to rostral diffusion when measured from 4-60 min after
infusion. In the present study the magnitude of alpha-1-agoni st
induced increases in acoustic startle correlated positively, within
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TABLE 4

Alterations in rat CNS norepinephrine levels after intrathecal adminis¬
tration of 6-OHDA.

Rats were infused intrathecally with 20ug of 6-OHDA in lOul 0.1% ascorbic
acid, sacrificed 2 weeks later, and the brain and spinal cord regions
dissected and stored at -70°C. Control rats were administered the same
volumes of vehicle solution. KE levels were determined as described in
the text. Values are mean ± S.E.M. of 9 animals.

Region

Norepinephrine levels
(ng/g wet weight)
Control

Lesion

A*

Cortex

240 ± 19

228 ± 24

-5

Brainstem

293 ± 11

286 ±

11

-2

Lumbar spinal cord

103 ± 10

4 ±

**Significantly different from control.

P<0.001.

1**

-96
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animals, to the number of 3H-prazosin binding sites occupied by that
agonist.

Intrathecal administration of 6-OHDA caused a marked and

selective decrease in spinal NE and an increase in the number of
3H-prazosin binding sites with no change in their affinity.

From 3

days to 4 weeks after 6-OHDA the number of 3H-prazosin binding sites
and the behavioral effects of phenylephrine increased linearly in a
highly correlated fashion.

Hence, under these conditions, changes in

alpha-1-adrenoceptor number was closely associated with changes in
functional alpha-1-adrenergic transmission.

The increase in acoustic startle following denervation correlated
with a change in the number of receptors without any change in the
affinity for the ligand.

Behavioral supersensitivity has also been

found following denervation or prolonged receptor blockade, which can
be correlated with changes in receptor number rather than receptor
affinity (11,44).

In summary, the present results document that a behavioral
supersensitivity to an alpha-1

agonist produced by 6-OHDA is directly

correlated with an increase in the number of alpha-1-adrenoceptors.
Given the ability of this system to analyze supersensitivity leading
to increased alpha-1 receptors and increased behavioral responsiveness
it was then decided to test whether the opposite response could be
observed and critically examined:

the phenomenon of behavioral

desensitization.

Experiment _3:

Alpha-1

adrenergic stimulation of acoustic startle in

desensitized and normal animals: behavior and binding studies.
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Previous biochemical and Dhysiological studies have shown that
prolonged exposure of receptor sites to certain neurotransmitters or
their agonists results in decreased responsiveness or desensitization
to these substances (7,8,31,43,58).

In a number of neurotransmitter

systems, desensitization has been shown to be associated with
decreases in the number of receptor sites as measured by radioligand
binding techniques (7,31,^3,53,58).

At a behavioral level,

desensitization or tachyphylaxis has been frequently observed.
However, a number of mechanisms could account for such decreases in
behavioral responsivity.

To determine whether behavioral

densensitization is associated with a decrease in receptor density it
is necessary to examine a system in which behavioral changes in drug
responsivity are highly correlated with changes in receptor number.
As has just been shown denervation supersensitivity to the excitatory
effects of the alpha-1- agonist phenylephrine on the acoustic startle
reflex is highly correlated with the number of 3H-prazosin binding
sites in the lumbar spinal cord.

Thus the effects of intrathecal

phenylephrine on the acoustic startle reflex represents a specific
method to probe alpha-1- adrenoceptor sensitivity which is correlated
with receptor density.

By exposing the animal to phenylephrine and then reintroducing it
several hours later it was hoped that behavioral desensitization could
be induced.

Once induced, given the ease of analysis the acoustic

startle system affords,

it should be possible to observe whether or

not a change in receptor density occurs.

Testing Procedure.
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One week following implantation the rats were divided into two
groups which received either intrathecal saline or 50 ug of
phenylephrine dissolved in 10 ul of saline (pH 7.4).

Six hours later

the animals were placed in the startle test cages and 5 min later a
program began which gave startle-eliciting noise bursts every 20 sec
for 14 min.

This constituted the pre-drug baseline.

Based on the

average startle performance across this baseline period the two
pretreatment groups were divided into two groups that had roughly
comparable baselines creating a total of four groups.

The rats were

then removed from their cages and infused a second time with either 50
ug phenylephrine (i.e., Groups SAL-PE and PE-PE) or saline (Groups
SAL-SAL and PE-SAL) .

Two additional groups of rats were infused with

phenylephrine or saline without any prior saline infusion to assess
the importance of this treatment.

All animals were tested for

acoustic startle at approximately the same time of day in order to
eliminate any possible influence of diurnal variation in the
behavioral response.

Immediately following the final infusion animals

were returned to their test cages and given noise bursts every 20 sec
for 30 min. Previous work has shown PE’s maximal stimulatory effect
occurs approximately 20 min following drug infusion.

Therefore, the

mean startle amplitude from 15 to 30 min after the drug infusion for
each rat was compared with that rat’s mean pre-drug infusion score to
determine the change in startle amplitude following treatment.

As shown in Figure 7,

intrathecal administration of 50 ug PE

increased startle amplitude about 80% over the predrug baseline while
saline treated animals showed the typical decline in startle amplitude
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by about 40$ over the same test period,
under these test conditions (4).

indicative of habituation

Animals infused with saline 6 hrs

previously (Group SAL-PE) were not significantly different in their
responses to intrathecal phenylephrine compared to their respective
non-preinfused counterparts (Group "--PE";

p <

.10).

Animals

preinfused with PE, however, were barely responsive to another PE
infusion 6 hrs later, and significantly different in their response to
PE compared to rats pre-inf used with saline, (Group SAL-PE vs. PE-PE:
t (14)

= 5.59, p < .001).

The lack of effect of PE in these animals

did not result from an elevation in their baselines produced by the
earlier PE infusion.

The effect of PE had dissipated by 6 hrs and in

fact the baselines of Groups PE-PE and SAL-PE prior to their second
infusion were essentially identical (data not shown).

These results

indicate marked desensitization following prior exposure to PE.

To assess the specificity of desensitization, a similar
experiment was done using the indirect alpha-1-agonist d-amphetamine
(dAMP) as the test drug 6 hrs following phenylephrine.

Intrathecal

d-amphetamine has been shown to increase startle and this effect can
be blocked by WB-4101 but not by haloperidol, cyproheptadine or
propranolol, indicating that an alpha-1- adrenergic receptor is
involved (4,15).

Fig. 8 confirms this in showing that both

phenylephrine or d-amphetamine increase startle when given
intrathecally in unpretreated animals.

Most importantly, however,

d-amphetamine had little effect in animals pretreated with
phenylephrine as indicated by a significant difference in the response
to dAMP in rats pretreated with saline vs PE (SAL-dAMP vs.

PE-dAMP;

t
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FIGURE 7.
Mean percent change in startle amplitude following intra¬
thecal infusion of the test drugs: saline (SAL) or phenylephrine (PE).
The test drugs were given with no pretreatment or 6 hours after
intrathecal infusion of PE. Percent change in startle amplitude from
15 to 30 minutes after the test drug with the mean startle amplitude
over the 14 minute period prior to the test drug.
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FIGURE 8.
Mean percent change in startle to various test drugs
(phenylephrine — PE; d-amphetamine — d-AMP; strychnine — STRY;
or 5-methoxydimethyltryptamine — 5-MEO) after different pretreat¬
ments. Pretreatment 1 consisted of intrathecal infusion of PE 6
hours prior to Pretreatment 2. Pretreatment 2 consisted of intra¬
thecal infusion of SAL, PE, or d-AMP 30 minutes prior to intrathecal
infusion of the test drugs. Percent change in startle (iS.E.M.) was
computed by comparing the mean 6tartle amplitude from 15 to 30
minutes after the test drug with the mean startle amplitude over
the 14 minute period prior to the test drug.
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(16)

= 4.41, p < .001).

This indicates that cross tolerance occurred

between phenylephrine and the indirectly acting alpha-1-adrenergic
agonist d-amphetamine.

To more fully test specificity, the PE-dAMP and the PE-PE rats
were given a final intrathecal infusion of either strychnine 6.25 ug
(STRY - a glycine antagonist) or 5-methoxy-N,N-dimethyltryptamine 50
ug (5-MeoDMT - a 5~HT agonist).

Both drugs have previously been found

to increase acoustic startle when administered intrathecally to
unpretreated rats (16,34).

Fig. 8 shows that both drugs still

increased startle in rats that were tolerant to d-amphetamine or PE (t
(6)

= 2.67, p < .05 for strychnine, t (10)

5-MeoDMT).

= 2.60, p < .02 for

This indicates that the desensitizing effect of prior

exposure to alpha-1-agonists did not generalize to drugs that act
through glycine or 5~HT receptors.

One possible explanation for the desensitization reported above
is that the alpha-1-adrenergic receptors involved in the modulation of
startle have decreased in number or undergone a conformational change
following prior exposure to PE, rendering them less responsive in
subsequent challenge tests.

To evaluate this possibility Scatchard

analysis of alpha-1-adrenoceptor sites and phenylephrine competition
curves were performed on lumbar spinal cord tissue taken from other
groups of animals 6 hrs following either intrathecal saline or 50 ug
of intrathecal phenylephrine.

At 6 hrs following 50 ug of intrathecal phenylephrine or saline
infusion animals were killed by decapitation and a 2.5 cm section of
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Q

lumbar cord was dissected out, weighed and frozen for subsequent JHprazosin assays.

Animals were sacrificed at the same time of day that

the behavioral experiments were run in order to minimize reported
circadian variations of B

values (32).

Lumbar spinal cord tissues

for each treatment group (5-6 rats) were pooled and homogenized in
cold 1:200 (w/v) of Tris HC1 buffer (pH 7.4), centrifuged at 42,000 x
g for 10 minutes, resuspended and centrifuged two additional times.
Control experiments indicated that any phenylephrine remaining in the
tissue was completely removed from the crude membrane preparations by
these washing procedures.

The resulting washed membrane pellets were

resuspended in cold 1:40 (w/v) 50 mM Tris HC1 buffer (pH 8.0).
Aliquots (0.8 ml) of this homogenate were incubated in the presence of
ascorbic acid (0.1$) and varying concentrations of
to 1.0 mM)

H- prazosin (0.05

(Amersham-Searle, S.A., 20.2 Ci/mM) and 0.05 M Tris HC1

buffer (pH 8.0) to 1.0 ml total volume.
assessed by the addition of 1 uM WB-4101.

Non-specific binding was
Quadruplicate sample and

triplicate non-specific binding values were obtained for each
concentration of

3

H- prazosin.

temperature for 30 min.

Incubations were carried out at room

After incubation the samples were rapidly

filtered through GF/B filters (Waltham Co., U.K.) under low vacuum.
The filters were washed with three 6 ml aliquots of ice cold 50 mM
Tris buffer (pH 7.4) and counted in a liquid scintillation counter in
8 ml Econofluor (New England Nuclear). The maximum number of binding
sites (B

) and apparent dissociation constant (Kn) were estimated by

Scatchard analysis.

Values were obtained from four separate

experiments, each with 5-6 animals per treatment group.

Protein

concentrations were determined by the method of Lowry et al.

(38).

0
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Pooled tissue from PE and saline pretreated animals were analyzed
for

->ti-

prazosin binding and its abililty to be displaced by the _in

vitro addition of various concentrations of phenylephrine.

Washed

lumbar cord membranes were prepared as described above and incubated
in the presence of 1

•3

nM JH-prazosin and various concentrations of

phenylephrine (1 x 10(— 3) M to 1 x 10(—6) M) in the presence or
absence of 1

uM WB—4101.

The Scatchard plot in Fig. 9 shows a decrease in the number of
prazosin binding sites in animals pretreated with phenylephrine 6 hrs
prior to sacrifice without a significant change in the affinity of the
receptor for the antagonist (Saline:
= 0.57 nM vs Phenylephrine B
nM).

max

B

IT13.X

= 56.5 fmols/mg protein, Kn
U

= 43.9 fmoles/mg protein, Kn = 0.48
u

In addition, the Ki for phenylephrine was similar in PE

pretreated (3.5 nM) and in saline pretreated (3-8 nM) animals (p <
0.1),

indicating no change in the affinity of binding sites for

phenylephrine following agonist pretreatment.

The purpose of the present study was to determine whether
specific desensitization of alpha-1-receptors could be induced and
observed in a behavioral paradigm:

the acoustic startle response.

Consistent with previous data, intrathecal administration of the
alpha-1-adrenergic agonist phenylephrine or the indirect alpha-agonist
d-amphetamine increased the amplitude of the acoustic startle response
in animals receiving no pretreatment or an intrathecal saline
pretreatment 6 hrs prior to startle testing.

Such excitatory effects

of intrathecal phenylephrine on startle can be blocked by systemic
administration of the alpha-1-adrenergic antagonist WB-4101, but not

B/F (fmole/mg protein/nM)
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FIGURE 9.
Scatchard analysis of [%]prazosin binding to rat lumbar
spinal cord membranes from animals treated 6 hours previously with
either intrathecal saline or 50ug of intrathecal phenylephrine
dissolved in saline. B/F is the ratio of specifically bound [%]prazosin to free [^Hjprazosin. The slope of each individual plot
gives an estimate of the equilibrium dissociation constant (Kp at
25°C). The intersection aith the abcissa gives a measure of the total
number of binding sites (Bmax). The post saline K^= 0.57 nM,
Broav- 56.5 fmoles/mg protein. The post PE Kp* 0.48 nM, Bffiax=43.9
fmoles/mg protein.
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by haloperidol, propranolol, yohimbine or cyproheptadine (4,15).

This

behavioral effect of phenylephrine represents, therefore, a specific
method to probe alpha-1-adrenergic receptor sensitivity.

In the

present study however, pretreatment of animals with intrathecal
phenylephrine dramatically decreased the normal stimulatory effect of
an alpha-1-agonist infused 6 hrs later.

These same animals,

unresponsive to either phenylephrine or d-amphetamine, were still able
to respond to intrathecal infusion of the glycine antagonist
strychnine or the serotonin agonist 5-MeoDMT with significant
increases in startle magnitude.

These results satisfy,

therefore,

Waud’s criteria for distinguishing specific from non-specific
desensitization (66).

Three representative drugs (an alpha-1-agonist,

a serotonin agonist and a glycine antagonist) produce the same
response (increase in startle magnitude) by interacting with three
different receptors while desensitization of the response to one
(alpha-1-agonist) is not accompanied by desensitization to the other
two.

Using

v

H- prazosin as a marker for alpha-1-adrenergic binding

sites it was shown, through Scatchard analysis, that the number of
alpha-1-adrenergic binding sites was decreased 6 hrs following an
intrathecal phenylephrine infusion without a change in the binding
sites'

affinity for the antagonist.

In addition, agonist affinity was

also unchanged as observed through the use of phenylephrine
competition curves.
GENERAL DISCUSSION

V
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The results of these experiments may be summarized as follows:

Experiment 1_:

showed that both serotonin and its agonist

5-Methoxy DMT and norepinephrine and its alpha-1

agonist phenylephrine

produced dose dependent increases in acoustic startle amplitude when
administered directly onto the lumbar spinal cord.

These effects were

specific as they were blocked by their respective antagonists but not
by antagonists of other transmitter systems.

Dopamine and its agonist

apomorphine were without effect on acoustic startle when administered
intrathecally.

Experiment 2:

demonstrated that intrathecal administration of

6-OHDA caused a marked and selective depletion of spinal NE with a
concomitant increase in the number of 3H-prazosin binding sites with
no change in their affinity.

The behavioral effects of phenylephrine

increased linearly in a highly correlated fashion with the number of
3H-prazosin binding sites.

Changes in alpha-1-adrenoceptor number was

closely associated with changes in functional alpha-1
transmission.

adrenergic

In addition, a high correlation was found between

receptor occupation and behavioral response to intrathecal
d-amphetami ne.

Experiment 3:

showed that specific desensitization to alpha-1

receptors could be induced and observed in the acoustic startle
response paradigm.

The desensitization induced by pretreatment with

phenylephrine was specific in that only the direct alpha-1
phenylephrine and the indirect alpha-1

agonist

a gonist d-amphetamine no longer

proved efficacious in increasing startle amplitude while 5~MeODMT and
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strychnine were still able to markedly augment acoustic startle
amplitude.
alpha-1

This desensitization was accompanied by a decrease in

adrenergic binding sites without an observed change in

receptor affinity.

The way in which serotonin, norepinephrine and their agonists
enhance the startle response is most probably similar to that proposed
for the modulation of cell firing in the facial motor nucleus
these motor cells,

(12). On

iontophoretic administration of 5~HT or NE does not

have any direct excitatory effects.

However, such treatment does

markedly increase excitation that is produced by electrical
stimulation of afferents to these cells.

Essentially identical

modulatory effects of NE and 5-HT have also been reported for lower
motor neurons in the spinal cord (18).

In the case of acoustic

startle, therefore, intrathecal administration of 5~HT or NE or their
agonists should amplify the effects of the afferent volley to these
neurons initiated by presentation of the acoustic startle stimulus.
This interpretation is also consistent with the finding that 5~HT and
NE increase the amplitude of spinal reflexes in spinal or decerebrate
animals (2,3»40,52).

These effects also involve specific agonist receptor interactions
as 5-HT antagonists block the effects of 5-MeODMT but not PE and
alpha-1 antagonists block PE's effect but not 5-MeODMT.

It is

interesting to note that in the present study propranolol did not
block the excitatory effect of intrathecal 5-MeODMT while previous
work has shown that systemic pretreatment with propranolol antagonizes
the increased startle caused by systemically administered 5-MeODMT
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(16).

Propranolol has also been shown to block the syndrome caused by

systemically administered 5-MeODMT or 5~HT precursors and a monoamine
oxidase inhbiitor (25).

Microiontophoretic work has shown, however,

that propranolol is ineffective in blocking the facilitation of the
facial motor nucleus caused by direct application of 5-HT or 5~HT
agonists (G.K. Aghajanian, personal communicati on).

It would seem,

therefore, that the antagonism caused by propranolol found in some
studies may be a secondary effect related to systemic administration
of both propranolol and 5-MeODMT.

In contrast to 5~HT and NE, neither DA nor the DA agonist
apomorphine increased acoustic startle when given intrathecally. This
is particularly interesting, since apomorphine is known to increase
both acoustic and tactile startle when given systemically (14,24), and
this effect can be blocked by either the DA antagonist, haloperidol
(14) or the alpha-1 antagonist phenoxybenzamine (35).

Perhaps

apomorphine increases startle by acting through a DA receptor in the
brain which is then expressed by release of NE in the spinal cord.
This hypothesis could be tested by seeing whether intrathecal NE
antagonists would block the effects of systemic apomorphine.

In fact,

the present results open up the possibility that a variety of drug or
environment manipulations that increase startle (e.g., sensitization
to background noise, potentiation due to prior conditioning) might be
expressed by release of 5~HT and/or NE into the spinal cord.

Again,

the technique of administering intrathecal antagonists could be used
to test this directly.
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The second group of experiments allowed the information gathered
in the first series to be applied in an effort to more clearly
understand the role of receptors and the drug-receptor complex in
mediating specific behavior.

It offered a number of opportunities to

determine the relationship between the degree of receptor occupation
and behavioral output.

Since in these studies, in vitro membrane

preparation was required, the true degree of in vivo receptor
occupation could not be determined.

During homogenization and

incubation, drug which was not initially bound to receptors in vivo
could compete for binding sites in the _in vitro assay.
'washed'

minus

'unwashed'

However, our

procedure does give an estimate for the

raaximimum possible drug occupation of binding sites in the spinal cord
membrane preparation.

In each case, the percentage of

alpha-1-adrenergic binding sites estimated to be occupied in animals
exhibiting full potentiation of startle was about 30%.

This figure

was calculated when, either d- amphetamine or phenylephrine was used to
increase startle.

It also occurred in animals treated with 6-OHDA.

Moreover, the Ki values for phenylephrine in lesioned and non-lesioned
animals were similar, despite the large increase in receptor number
after 6-OHDA treatment.

Thus, the ability of phenylephrine to

displace 3H-prazosin in _in vitro preparations of tissue from lesioned
and non-lesioned animals was .constant.
of 'spare receptors',

These data support the concept

in which only a fraction of the total number of

receptors need to be occupied to give a full biological effect,
consistent with data in other transmitter systems.

Thus Paul et al.,

(48) has shown that a 30% occupation of benzodiazepine binding sites
was sufficient to protect against drug induced seizures in mice.
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Venter (64) found that only 10$ of cardiac beta receptors were needed
to provide the full inotropic and cyclic AMP responses elicited by
isoproterenol.

Furchgott (23) using irreversible alpha adrenergic

receptor antagonists found that more alpha receptors existed than were
required for complete tissue activation in certain peripheral
systems.

In the present experiments, the magnitude of startle facilitation
produced by a rather low dose of phenylephrine 4 weeks after 6-OHDA
was actually higher than the maximal degree of facilitation seen after
any dose in normal rats.

Functionally, therefore, denervation

resulted in an increase in the efficacy of phenylephrine along with an
increase in potency.

For example, in normal rats, the maximal startle

increase caused by intrathecal phenylephrine was about 100$ above
baseline even at the highest doses tested. In contrast, a dose of only
12.5 ug increased startle by about 160$ in rats treated with 6-OHDA 4
weeks earlier.

There may be several reasons why higher doses of phenylephrine
are not able to increase startle above about 100$ in normal rats.

One

possibility is that high doses were observed to elicit behaviors such
as twitching and panting which may compete with the expression of the
startle response.

Thus, at high doses, these behaviors may subtract

from the increase in startle expected.

However, if these competing

behaviors are not due to specific occupation of alpha-1-receptor
sites, then one should not expect supersensitivity of these behaviors
to develop following alpha-1-receptor site proliferation. Equivalent
receptor occupancy in normal and 6-OHDA treated rats would result in a
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greater absolute number of binding sites occupied by phenylephrine in
denervated rats.

Since the magnitude of startle change is directly

related to the absolute number of alpha-1-binding sites, then a low
dose of phenylephrine could result in a large (supranormal) increase
in startle without eliciting incompatable behaviors.

Another possibility to explain the lack of large doses of
agonists in bringing out maximal behavioral changes is the phenomenon
of receptor desensitization,

involving changes in receptor recognition

sites (28), and/or coupling steps beyond the receptor (21,22).

Such

desensitization processes are both time and dose dependent (22).

Thus

the inability to see large changes in startle following high doses of
phenylephrine could result from desensitization.

In 6-OHDA-treated

rats, comparable numbers of receptors could be occupied by lower and
hence less desensitizing doses of phenylephrine.

The results of the third series of experiments do indeed show
that desensitization can occur in intrathecally implanted animals and
that this desensitization does involve changes in the number of
reeptor recognition sites.

These results support the work of others

who have shown decrease in receptor number to accompany
desensitization.

Kababian et al.

(31) working with the rat pineal

beta-adrenergic-receptor, observed rapid subsensitivity that developed
within hours and which correlated with progressively fewer
beta-adrenergic-binding sites.

Mickey et al.

(43) studying

catecholamine tolerance in the purified frog erythrocyte system, also
found a correlation between desensitization and declining
beta-adrenergic-receptor binding.

These workers hypothesized that a
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reduction in receptor binding is a major mechanism in the induction of
desensitization to catecholamines.

As in our study, receptor affinity

for either agonist or antagonist was reported to be unchanged.

Thus

it appears that decrease in receptor number can occur in desensitized
systems.

However,

in our studies, only a small absolute decrease in

receptor binding density (22%) accompanied the complete
desensitization of the behavioral resonse to phenylephrine.
Experiment two showed that occupation of a minimum number of alpha-1
adrenoceptor sites by the agonist is necessary to produce a net
increase in the startle response.

It is therefore possible that only

a small decrease in receptor density could result in a sub-threshold
activation of alpha-1 adrenoceptors for changing startle.

Thus small

decreases in receptor number could result in desensitization of the
behavioral response, as observed in the present study.
also possible that,

However,

it is

in addition to changes in receptor density,

coupling steps beyond the receptor may be involved in the
desensitization processes (22).
under investigation.

Such possibilities are currently

From the present study, however, it is clear

that the ability to study behavior, pharmacology and biochemistry in
the acoustic startle system makes it a powerful tool in the study of
receptor mechanisms and other aspects of central nervous system
plastici ty.

V
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